Predictors of renal and patient outcomes in anti-neutrophil cytoplasmic antibody-associated vasculitis: Our single-center, tertiary care experience

Simple item page
dc.contributor.authorToraman A.
dc.contributor.authorGündüz Ö.S.
dc.date.accessioned2024-07-22T08:05:54Z
dc.date.available2024-07-22T08:05:54Z
dc.date.issued2021
dc.description.abstractObjectives: This study aims to assess the different predictors of renal and patient prognosis in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) patients with and without renal involvement. Patients and methods: A total of 79 patients (51 males, 28 females; mean age: 57.3±14.2 years; range, 18 to 71 years) with AAV between January 2006 and November 2019 were retrospectively analyzed. Demographic and laboratory data including the complement 3 (C3) serum levels and renal biopsy findings were extracted from the electronic and printed medical records of the hospital registry. Survival, renal survival, remission, and relapse outcomes were analyzed. Results: A total of 35% of the patients with renal involvement progressed to end-stage renal disease (ESRD). The dialysis requirement at the time of admission (hazard ratio [HR]: 21.95 [2.93-164.22]; p=0.003), estimated glomerular filtration rate (eGFR) (HR: 0.97 [0.94-0.99]; p=0.024) and Five-Factor Score (FFS) ≥2 at the time of diagnosis (HR: 3.59 [1.08-11.94]; p=0.037) were the predictors of ESRD. The five-year patient survival rate was 87.1%. The only predictor of mortality was age (HR: 1.07 [1.01-1.14]; p=0.024). The patients with hypocomplementemia (22%) had a lower remission rate (p=0.049), FFS ≥2 at the time of diagnosis (p=0.026), and higher levels of hematuria (p=0.004) and proteinuria (p=0.037). The FFS ≥2 at the time of diagnosis was an independent predictor of relapse (HR: 8.9 [1.02-77.36]; p=0.047). Conclusion: Our study suggests that the baseline renal function and FFS ≥2 at the time of diagnosis are the major prognostic factors for progression to ESRD in AAV patients. In addition, AAV patients with hypocomplementemia may have a lower remission rate. © 2021 Turkish League Against Rheumatism. All rights reserved.
dc.identifier.DOI-ID10.46497/ArchRheumatol.2021.8687
dc.identifier.issn21485046
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13284
dc.language.isoEnglish
dc.publisherTurkish League Against Rheumatism (TLAR)
dc.rightsAll Open Access; Gold Open Access; Green Open Access
dc.subjectalbumin
dc.subjectantinuclear antibody
dc.subjectazathioprine
dc.subjectC reactive protein
dc.subjectcomplement component C3
dc.subjectcomplement component C4
dc.subjectcreatinine
dc.subjectcyclophosphamide
dc.subjectferritin
dc.subjectglucocorticoid
dc.subjecthemoglobin
dc.subjectmethotrexate
dc.subjectmyeloblastin
dc.subjectmyeloperoxidase
dc.subjectneutrophil cytoplasmic antibody
dc.subjectrituximab
dc.subjectadult
dc.subjectaged
dc.subjectANCA associated vasculitis
dc.subjectarthralgia
dc.subjectarthritis
dc.subjectArticle
dc.subjectblood cell count
dc.subjectcardiovascular disease assessment
dc.subjectcomputer assisted tomography
dc.subjectconjunctivitis
dc.subjectdialysis
dc.subjectend stage renal disease
dc.subjectepiscleritis
dc.subjecterythrocyte sedimentation rate
dc.subjectestimated glomerular filtration rate
dc.subjectfemale
dc.subjectFive Factor Score
dc.subjectglomerulonephritis
dc.subjecthearing impairment
dc.subjecthematuria
dc.subjecthemodialysis
dc.subjecthistopathology
dc.subjecthuman
dc.subjecthuman tissue
dc.subjecthypertension
dc.subjecthypocomplementemia
dc.subjectimmunofluorescence
dc.subjectimmunosuppressive treatment
dc.subjectintestine infarction
dc.subjectintestine ischemia
dc.subjectintestine perforation
dc.subjectkidney biopsy
dc.subjectkidney failure
dc.subjectkidney function
dc.subjectleukocyturia
dc.subjectlung hemorrhage
dc.subjectlung nodule
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmiddle aged
dc.subjectmortality
dc.subjectmyocarditis
dc.subjectnuclear magnetic resonance imaging
dc.subjectpericarditis
dc.subjectplasmapheresis
dc.subjectprognosis
dc.subjectproteinuria
dc.subjectpurpura
dc.subjectrash
dc.subjectrecurrence free survival
dc.subjectrelapse
dc.subjectremission
dc.subjectrenal replacement therapy
dc.subjectretina vasculitis
dc.subjectretrospective study
dc.subjectscleritis
dc.subjectsinusitis
dc.subjectskin ulcer
dc.subjectsubglottic stenosis
dc.subjectsurvival
dc.subjectsurvival rate
dc.subjecttreatment outcome
dc.subjecturinalysis
dc.subjectuveitis
dc.subjectvasculitis
dc.titlePredictors of renal and patient outcomes in anti-neutrophil cytoplasmic antibody-associated vasculitis: Our single-center, tertiary care experience
dc.typeArticle

Files

Collections

Scopus Koleksiyonu